[Gastrointestinal motility disorders and drugs: cholinergic, anticholinergic, adrenergic, antiadrenergic and prokinetic drugs (part I)].
The review deals with gastrointestinal receptors which are of therapeutic interest for the treatment of motility disorders. It updates the present knowledge of muscarinic, adrenergic and dopaminergic receptors, their subtypes, cellular sites and functional role as drug targets. On the basis of this pharmacological concept, drugs, mainly agonists and antagonists, are evaluated in proven and potential indications. In view of the very complex regulation of motility, our understanding of receptors is still fragmentary and our tools to treat motility disorders do not fulfil all therapeutic requirements. This review tries to point out the areas of particular need for further basic research and the prospects of further drug development.
Jovanović-Mićić
D
D
Janković
S
S
Beleslin
D B
DB
D018663:Adrenergic Agents / Q000627:therapeutic use; D018674:Adrenergic Antagonists / Q000627:therapeutic use; D018678:Cholinergic Agents / Q000627:therapeutic use; D018680:Cholinergic Antagonists / Q000627:therapeutic use; D005765:Gastrointestinal Agents / Q000627:therapeutic use*; D005767:Gastrointestinal Diseases / Q000188:drug therapy*; D005769:Gastrointestinal Motility / Q000187:drug effects*; D006801:Humans
D018663:Adrenergic Agents; D018674:Adrenergic Antagonists; D018678:Cholinergic Agents; D018680:Cholinergic Antagonists; D005765:Gastrointestinal Agents